News
February 19, 2024
EPOK Therapeutics appoints four renowned experts to Scientific Advisory Board
Details
Toronto (Canada) / Hayward (CA, USA) – EPOK Therapeutics Inc., a preclinical stage biologics company developing advanced antibody formats targeting anemia and phosphate disorders, announced today the appointment of four renowned experts to its Scientific Advisory Board (“SAB”).
February 5, 2024
EPOK Therapeutics Inc. is Recognized as the Top Therapeutic Company in Canada by Life Sciences Review Top Therapeutic Company
Details
The company’s presence spans the innovation hubs of the bay Area in California and Texas and several development partners in the US and Europe, reinforcing its commitment to maintaining a global drug discovery and development perspective.
April 10, 2023
EPOK Therapeutics raises $9.0M in Seed Round Financing.
Details
EPOK Therapeutics Inc. (“EPOK” or the “Company”), a preclinical stage biotech company developing diabodies and antibody conjugates, announced today the completion of a $9.0M Seed Round financing, led by Canadian and Italian angel investors.
The proceeds from the financing will support the preclinical development of two proprietary drug candidates.
In conjunction with the financing, the Company appointed a new Board of Directors, with Alessandra Gavirati as Chair, Surya Sankuratri as CEO, co-Founder Sachdev Sidhu as Chief ScientiRic OfRicer, and Luigi Colombo as Chief Operation Officer. Co-Founder Orson Moe will serve as Chief Medical Officer.